Jefferies Financial Group Inc. Makes New $4.90 Million Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

Jefferies Financial Group Inc. purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 202,630 shares of the company's stock, valued at approximately $4,900,000. Jefferies Financial Group Inc. owned approximately 0.09% of Hims & Hers Health as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in HIMS. Vanguard Group Inc. lifted its position in Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after acquiring an additional 2,020,722 shares during the last quarter. Farallon Capital Management LLC grew its position in shares of Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after purchasing an additional 8,364,000 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Hims & Hers Health by 29.0% in the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after purchasing an additional 1,562,302 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in shares of Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after purchasing an additional 4,145,305 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Hims & Hers Health by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock valued at $104,724,000 after purchasing an additional 40,447 shares during the period. Institutional investors and hedge funds own 63.52% of the company's stock.

Insiders Place Their Bets

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $33.98, for a total transaction of $4,353,755.46. Following the sale, the chief executive officer now owns 173,655 shares of the company's stock, valued at $5,900,796.90. This represents a 42.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Irene Becklund sold 2,203 shares of the firm's stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $28.78, for a total transaction of $63,402.34. Following the completion of the sale, the insider now owns 8,007 shares of the company's stock, valued at $230,441.46. The trade was a 21.58% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 606,704 shares of company stock valued at $24,621,075. 13.71% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have commented on HIMS. Wall Street Zen raised Hims & Hers Health from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Bank of America raised their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research note on Tuesday, April 29th. TD Cowen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating and cut their target price for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Piper Sandler reissued a "neutral" rating and issued a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Finally, UBS Group restated a "mixed" rating on shares of Hims & Hers Health in a report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $37.67.

Hims & Hers Health Trading Down 0.8%

HIMS stock traded down $0.42 during trading on Thursday, hitting $52.92. The company had a trading volume of 10,377,684 shares, compared to its average volume of 19,600,576. The company has a fifty day moving average price of $39.15 and a two-hundred day moving average price of $35.63. Hims & Hers Health, Inc. has a fifty-two week low of $13.47 and a fifty-two week high of $72.98. The company has a market cap of $11.85 billion, a P/E ratio of 120.03 and a beta of 1.84.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.12 by $0.08. The company had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm's revenue for the quarter was up 110.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.05 EPS. On average, analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.